Vancouver, Canada - September 27, 2018 - Aspect Biosystems, a leader in the field of 3D bioprinting and tissue engineering, is proud to be named BIOTECanada’s Emerging Company of the Year for 2018 as part of the annual Gold Leaf Awards. The Gold Leaf Awards highlight innovation and entrepreneurship within the Canadian biotechnology industry. This national celebration of the Canadian industry represents an outstanding collection of companies and individuals who have helped lead the industry throughout 2018.
"To be selected as BIOTECanada's Emerging Company of the Year, among so many notable biotech companies across the country, is a true honour," said Tamer Mohamed, Aspect's President and CEO. "We are inspired by the profound impact regenerative medicine therapies can have on patients around the globe and our team is committed to realizing this impact from right here in Canada."
Over the last 10 years, half of the winners for Emerging Company of the Year have been based in British Columbia.
Full list of 2018 BIOTECanada Gold Leaf Winners:
“The remarkable individuals and companies we recognize through the Gold Leaf Awards are great examples of the core strengths of Canada’s biotech ecosystem including scientific excellence and passion,”commented Andrew Casey, President and CEO of BIOTECanada. “Importantly,Canada’s global biotech success is founded in its ability to advance scientific innovation by leveraging a diverse and vibrant ecosystem comprised of individuals, companies and institutions located in every province across the country. It is this strength that establishes Canada’s biotech industry as a leader in developing the solutions that will help address the global social and economic opportunities emerging from population growth and a changing climate.”
Read the press release from BIOTECanada here.
Aspect Biosystems is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal tissue development programs,Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used for impactful applications in therapeutic discovery and regenerative medicine. www.aspectbiosystems.com